Analytical Data
-
Gene name
GPR39
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43194
-
Expression Region
Ile304~Val453
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPR39, a member of the G protein-coupled receptor (GPCR) family, has garnered significant attention in recent years due to its unique role in various physiological processes. Initially identified as an orphan receptor, GPR39 is primarily activated by zinc ions and is implicated in the regulation of several biological functions, including food intake, energy metabolism, and neuroprotection. Research has shown that GPR39 plays a crucial role in maintaining metabolic homeostasis and may influence conditions such as obesity and diabetes. The receptor is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract, indicating its involvement in central and peripheral signaling pathways. The study of recombinant GPR39 proteins has become essential for understanding its structure-function relationships and signaling mechanisms. By producing and characterizing recombinant GPR39, researchers aim to elucidate the receptor's activation pathways, downstream signaling cascades, and potential therapeutic applications. Furthermore, the availability of GPR39 recombinant proteins paves the way for drug development and the exploration of novel pharmacological agents targeting this receptor to treat metabolic disorders. As such, GPR39 represents a promising target for innovative therapeutic strategies aimed at improving metabolic health and addressing the growing burden of related diseases.
